Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

ESSA Pharma Inc

Healthcare US EPIX

NoneUSD
0.00(0%)

Last update at 2025-11-13T20:09:11.988075Z

Day Range

--
LowHigh

52 Week Range

2.5811.67
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap267.51M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-23.50162M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.63

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax -26.58074M -35.21500M -36.83981M -23.73400M -10.40300M
Minority interest - - - - -
Net income -26.58234M -35.10300M -36.80546M -23.44500M -10.44100M
Selling general administrative 11.37M 12.54M 12.78M 11.37M 5.47M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.12M 0.12M 0.11M 0.11M 0.02M
Ebit -26.58033M -35.34279M -36.90857M -23.11532M -12.15230M
Ebitda -26.46184M -35.22100M -36.79911M -23.00500M -12.13400M
Depreciation and amortization 0.12M 0.12M 0.11M 0.11M 0.02M
Non operating income net other - - - - -
Operating income -26.58033M -35.34279M -36.90857M -23.11532M -12.15230M
Other operating expenses 32.13M 36.96M 37.14M 23.52M 12.17M
Interest expense 0.00694M 0.01M 0.02M 0.62M 0.60M
Tax provision 0.00160M -0.11182M -0.03435M -0.28865M 0.04M
Interest income 5.55M 1.74M 0.23M 0.56M 0.03M
Net interest income 5.55M 1.72M 0.21M -0.05839M -0.57649M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00160M -0.11200M -0.03435M -0.28900M 0.04M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 32.13M 36.96M 37.14M 23.52M 12.17M
Cost of revenue - - - - 0.07M
Total other income expense net 0.00653M 0.13M 0.07M -0.61868M 1.75M
Discontinued operations - - - - -
Net income from continuing ops -26.58234M -35.10325M -36.80546M -23.44537M -10.44186M
Net income applicable to common shares - -35.10325M -36.80546M -23.44537M -12.75683M
Preferred stock and other adjustments - - - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 149.12M 169.50M 198.17M 80.58M 54.77M
Intangible assets - - - - 0.20M
Earning assets - - - - -
Other current assets - 1.82M 2.18M 24.25M 1.45M
Total liab 3.50M 2.39M 4.16M 1.33M 5.59M
Total stockholder equity 145.63M 167.12M 194.01M 79.24M 49.18M
Deferred long term liab - - - - -
Other current liab 1.39M 1.22M 2.38M 0.00068M 0.30M
Common stock 278.16M 278.09M 277.42M 131.09M 76.21M
Capital stock 278.16M 278.09M 277.42M 131.09M 76.21M
Retained earnings -179.46136M -152.87902M -117.77577M -80.97030M -54.81095M
Other liab - - 0.02M 0.13M 0.02M
Good will - - - - -
Other assets 115.35M -0.44595M 198.17M -0.05516M -0.20073M
Cash 33.70M 57.08M 137.83M 56.32M 53.32M
Cash and equivalents - - - - -
Total current liabilities 3.50M 2.31M 3.93M 1.20M 5.58M
Current deferred revenue - - - - -
Net debt -33.62158M -56.86617M -137.49405M -56.26191M -49.61404M
Short term debt 0.08M 0.13M 0.12M 0.06M 3.71M
Short long term debt - - - - 3.71M
Short long term debt total 0.08M 0.21M 0.33M 0.06M 3.71M
Other stockholder equity 49.05M 44.04M 36.44M 31.20M 0.00010M
Property plant equipment - 0.19M 0.31M - -
Total current assets 148.80M 169.50M 197.60M 80.58M 54.77M
Long term investments - - - - -
Net tangible assets - 167.12M 194.01M 79.24M 48.98M
Short term investments 114.37M 110.16M 57.10M 22.01M -
Net receivables 0.14M 0.00621M 0.49M 0.31M 0.36M
Long term debt - - - - -
Inventory - 110.61M - -0.30954M -0.36080M
Accounts payable 2.03M 0.95M 1.43M 1.14M 1.57M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -2.12040M -2.13515M -2.07648M -2.07648M 27.78M
Additional paid in capital - - - - -
Common stock total equity - - - 131.09M 76.21M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.26M 0.26M 0.26M 0.28M -0.20073M
Deferred long term asset charges - - - - -
Non current assets total 0.33M 0.45M 0.57M 0.06M 0.20M
Capital lease obligations 0.08M 0.21M 0.33M 0.06M -
Long term debt total - - - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Investments -3.52715M -52.34839M -35.02610M -21.73725M -0.04551M
Change to liabilities - -1.62906M 2.67M -0.04636M -1.01405M
Total cashflows from investing activities - -52.34839M -35.01477M -21.73725M 0.20M
Net borrowings - -0.13402M -0.10028M -4.00718M -2.80882M
Total cash from financing activities -0.06816M 0.25M 141.99M 41.78M 50.81M
Change to operating activities - 0.37M -0.56357M -1.26228M -0.17942M
Net income -26.58234M -35.10325M -36.80546M -23.44537M -10.44186M
Change in cash -23.37456M -80.74855M 81.50M 3.00M 38.49M
Begin period cash flow 57.08M 137.83M 56.32M 53.32M 14.83M
End period cash flow 33.70M 57.08M 137.83M 56.32M 53.32M
Total cash from operating activities -19.78172M -28.70417M -25.41561M -16.98315M -12.24994M
Issuance of capital stock - 0.00000M 150.00M 48.99M 36.00M
Depreciation 0.12M 0.12M 0.11M 0.11M 0.02M
Other cashflows from investing activities - 0.71M 0.01M 0.27M 0.20M
Dividends paid - - 0.00000M 0.00000M 0.00000M
Change to inventory - - - - -
Change to account receivables - 0.48M -0.15757M 0.09M -0.05967M
Sale purchase of stock - - - - -
Other cashflows from financing activities 0.07M 0.39M -7.90895M -3.20619M 17.62M
Change to netincome - 7.06M 9.33M 7.59M 1.76M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 2.34M -0.78001M 1.95M -1.23870M -1.25785M
Stock based compensation 5.01M 7.89M 9.48M 7.52M 1.15M
Other non cash items 0.00732M -0.83078M -0.03529M 0.22M -1.73021M
Free cash flow -19.78172M -28.70417M -25.41561M -16.98315M -12.24994M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
EPIX
ESSA Pharma Inc		 - -% - - - - 2.48 -8.087
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

ESSA Pharma Inc

999 West Broadway, Vancouver, BC, Canada, V5Z 1K5

Key Executives

Name Title Year Born
Dr. David Ross Parkinson M.D. Pres, CEO & Director 1950
Mr. David S. Wood C.M.A., CPA, M.B.A., MBA, CPA, CMA Chief Financial Officer 1957
Mr. Peter A. Virsik M.B.A., M.S. Exec. VP & COO 1971
Dr. Alessandra Cesano M.D., Ph.D. Chief Medical Officer 1960
Chandtip Chandhasin Exec. NA
Erica Osbourne Exec. NA
Erin Rudsinski Exec. NA
Loleta Harris Exec. NA
Neil Thapar Exec. NA
Nkengyal Barber Exec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.